Ricardo Yaryura, MD
Cardiovascular Disease · Sarasota, FLNPI 1083662266
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (59.0%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Edwards Lifesciences at 52.2% of the total. 2025 is the largest year on record at $4,878, 7.2 times the $681 reported in 2019.
Across 205 payments — averaging $57.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$6K
- Abbott$2K
- Boston Scientific$587
- Pfizer$286
- Biotronik Inc.$264
- Abiomed$258
- plus $2K from 25 others
Across 194 payments — averaging $8182.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Edwards Lifesciences$1.3M
- CSL Behring$195K
- Boston Scientific$97K
- Abbott$7K
What the payments were for
- Consulting fees$2,65023%
- Travel & lodging$2,12918%
- Food & beverage$6,93059%
- Education$280%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 51 | $6,123 |
| Abbott | 48 | $2,248 |
| Boston Scientific | 14 | $587 |
| Pfizer | 12 | $286 |
| Biotronik Inc. | 5 | $264 |
| Abiomed | 6 | $258 |
| Impulse Dynamics (USA) Inc. | 2 | $242 |
| Cvrx, Inc. | 3 | $191 |
| Amgen | 10 | $180 |
| Novartis | 7 | $149 |
| Shockwave Medical, Inc | 3 | $136 |
| Cardiovascular Systems Inc. | 12 | $130 |
| Medtronic | 2 | $130 |
| AstraZeneca | 4 | $124 |
| Merck | 5 | $111 |
| Cardiva Medical, Inc. | 2 | $76 |
| Reflow Medical Inc | 1 | $66 |
| Teleflex LLC | 2 | $63 |
| Opsens Inc. | 1 | $53 |
| Scpharmaceuticals Inc. | 2 | $41 |
| Vasorum USA Inc. | 1 | $35 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $33 |
| Philips North America LLC | 1 | $30 |
| Kestra Medical Technology Services, Inc. | 1 | $28 |
| Terumo Medical Corporation | 1 | $27 |
| Biosense Webster, Inc. | 1 | $25 |
| Sanofi-aventis U.S. LLC | 1 | $25 |
| Penumbra, Inc. | 2 | $23 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $19 |
| Johnson & Johnson | 1 | $18 |
| Boehringer Ingelheim | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SAPIEN 3 Ultra RESILIA$2,120
- TRICLIP$793
- EVOQUE$647
- Edwards SAPIEN 3 Transcatheter Heart Valve$530
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$392
- PASCAL$349
- OPTIMIZER$343
- MitraClip$286
- Barostim Neo System$154
- Impella$136
- BioMonitor$132
- CARDIOMEMS$124
- LOTUS EDGE$123
- Watchman$123
- VYNDAQEL$120
How this compares
$11,736 in reported general payments places this provider in the 80th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 561 | $716,221 |
| EntrestoSacubitril/Valsartan | 195 | $263,742 |
| XareltoRivaroxaban | 198 | $256,904 |
| Repatha SureclickEvolocumab | 95 | $132,928 |
| FarxigaDapagliflozin Propanediol | 116 | $126,539 |
| Repatha PushtronexEvolocumab | 63 | $58,364 |
| JardianceEmpagliflozin | 43 | $51,279 |
| BrilintaTicagrelor | 46 | $42,721 |
| Praluent PenAlirocumab | 29 | $25,103 |
| MultaqDronedarone Hcl | 13 | $15,024 |
| NexletolBempedoic Acid | 12 | $11,243 |
| ClopidogrelClopidogrel Bisulfate | 823 | $10,209 |
| Rosuvastatin Calcium | 565 | $9,098 |
| Ezetimibe | 257 | $8,218 |
| Dofetilide | 18 | $7,716 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $286 | $716,221561 claims |
| NovartisEntresto | $149 | $263,742195 claims |
| Johnson & JohnsonXarelto | $18 | $256,904198 claims |
| AstraZenecaFarxiga, Brilinta | $124 | $169,260162 claims |
| Boehringer IngelheimJardiance, Pradaxa | $14 | $53,61955 claims |
| Sanofi-aventis U.S. LLCMultaq | $25 | $15,02413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Sarasota
- Manfouz El ShahawySarasota$116K
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Alan MillerJacksonville$547K
- Seth BaumBoca Raton$517K
- Elliott EliasMiami$497K
- Vijay HaryaniVero Beach$413K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.